• The Dish’s Weekly News Wrap Up – June 29, 2012

    “Measure to Increase FDA Funds Through New Company Fees Goes to Obama,” The Washington Post A measure that would generate $6 billion in fees over five years for the Food and Drug Administration is headed to President Obama...

    • Posted June 29, 2012
    • 0
  • New Strategies Key to the Clinical Manufacturing of Stem Cells for Therapeutic Use

    In May, Osiris’, Prochymal, made history by becoming the first approved stem cell therapy. The approval was first received in Canada, then New Zealand and is currently under review by the Food and Drug Administration (FDA) in...

    • Posted June 28, 2012
    • 13
  • The House Passes FDA User Fee Reauthorization Bill; Senate Next

    On June 20th, the House passed the Food and Drug Administration (FDA) User Fee Reauthorization Bill that reauthorizes user fee programs for both drug and medical device review. The Bill also establishes new user fee programs for...

    • Posted June 25, 2012
    • 7
  • The Dish’s Weekly News Wrap Up – June 22, 2012

    “Biotech Improved in 2011; Future Uncertain: Report,” Reuters The aggregate financial performance of biotechnology companies in four of the world’s major markets — the United States, Europe, Canada and Australia — improved in 2011, but funding for...

    • Posted June 22, 2012
    • 0
  • The Arduous Path to the Clinic – Plan Early to Avoid Late Attrition!

    A Guest Blog by Michel Fischbach, Chief Scientific Officer, TNCBio Stem cell therapies (SCTs) are heralded as the cure of the future for a large range of ailments that remain untreatable in the current therapeutic setting. Together...

    • Posted June 20, 2012
    • 4